Compare Organon Pharma Indonesia Tbk. (SCPI) vs Tigaraksa Satria Tbk. (TGKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Tigaraksa Satria Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Tigaraksa Satria Tbk. trades at Rp4,970 (market cap 4.56T, 300 24h volume). The key difference: Tigaraksa Satria Tbk. is far larger — about 43.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TGKA | |
|---|---|---|
Market Cap | 104.4B | 4.56T |
Volume | — | 300 |
Lot | — | 3 |
Turnover | — | 1.5M |
Average Price | — | 5,015 |
Value | — | 1.5M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Tigaraksa Satria Tbk.
PT Tigaraksa Satria Tbk (the Company) was established in Jakarta based on notarial deed No. 35 of M.M.I. Wiardi, S.H., dated November 17, 1986. PT. Tigaraksa Satria is a distributor of Nutrition, Chemicals, Cosmetic, Books, Garments and other consumer goods. Founded in 1987 as a subsidiary of PT. Tigaraksa, the company handles the dosmetic distribution products for more than 20 pricipals.
Read more on TGKA →
